1887

Abstract

Genital human papillomaviruses (HPV) are considered to be one of the main risk factors for the development of cervical cancer. The P97 promoter at the E6-proximal end of the long control region (LCR) regulates the transcription of viral genes, especially the oncogenes E6 and E7. The LCR contains binding sites of several viral and cellular transcription factors, which either activate or repress the P97 promoter. Intratype variants of HPV-16 belong to six geographically clustered phylogenetic groups distributed all over the world. These variants exhibit differences in E6 protein activities and in tumour progression . Seven HPV-16 variants were investigated by sequencing the entire LCR (nt 7060–124) and by comparing the transcriptional activities of their P97 promoters. Previously unknown nucleotide variations were identified in all LCRs investigated. In luciferase assays, 3·3- and 2·8-fold increases in P97 promoter activity were detected in the Asian American c and North American 1 variants when compared with the European reference clone. The African variants 1a and 2a exhibited P97 promoter activities comparable to the European reference clone. After recombining different LCR fragments, the region responsible for enhanced transcription in the Asian American c and North American 1 variants could be attributed to the E6-proximal end of the LCR (nt 7619–124).

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-81-8-1975
2000-08-01
2019-10-19
Loading full text...

Full text loading...

/deliver/fulltext/jgv/81/8/0811975a.html?itemId=/content/journal/jgv/10.1099/0022-1317-81-8-1975&mimeType=html&fmt=ahah

References

  1. Bauknecht, T., Angel, P., Royer, H.-D. & zur Hausen, H. ( 1992; ). Identification of a negative regulatory domain in the human papillomavirus type 18 promoter: interaction with the transcriptional repressor YY1. EMBO Journal 11, 4607-4617.
    [Google Scholar]
  2. Bauknecht, T., See, R. H. & Shi, Y. ( 1996; ). A novel C/EBP β-YY1 complex controls the cell-type-specific activity of the human papillomavirus type 18 upstream regulatory region. Journal of Virology 70, 7695-7705.
    [Google Scholar]
  3. Bosch, F. X., Manos, M. M., Muñoz, N., Sherman, M., Jansen, A. M., Peto, J., Schiffman, M. H., Moreno, V., Kurman, R. & Shah, K. V. ( 1995; ). Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. Journal of the National Cancer Institute 87, 796-802.[CrossRef]
    [Google Scholar]
  4. Chan, W.-K., Chong, T., Bernard, H.-U. & Klock, G. ( 1990; ). Transcription of the transforming genes of the oncogenic human papillomavirus-16 is stimulated by tumor promotors through AP1 binding sites. Nucleic Acids Research 18, 763-769.[CrossRef]
    [Google Scholar]
  5. Chong, T., Chan, W.-K. & Bernard, H.-U. ( 1990; ). Transcriptional activation of human papillomavirus 16 by nuclear factor I, AP1, steroid receptors and a possibly novel transcription factor, PVF: a model for the composition of genital papillomavirus enhancers. Nucleic Acids Research 18, 465-470.[CrossRef]
    [Google Scholar]
  6. Chong, T., Apt, D., Gloss, B., Isa, M. & Bernard, H.-U. ( 1991; ). The enhancer of human papillomavirus type 16: binding sites for the ubiquitous transcription factors oct-1, NFA, TEF-2, NF1, and AP-1 participate in epithelial cell-specific transcription. Journal of Virology 65, 5933-5943.
    [Google Scholar]
  7. Das, B. C., Sharma, J. K., Gopalkrishna, V. & Luthra, U. K. ( 1992; ). Analysis by polymerase chain reaction of the physical state of human papillomavirus type 16 DNA in cervical preneoplastic and neoplastic lesions. Journal of General Virology 73, 2327-2336.[CrossRef]
    [Google Scholar]
  8. de Wet, J. R., Wood, K. V., DeLuca, M., Helinski, D. R. & Subramani, S. ( 1987; ). Firefly luciferase gene: structure and expression in mammalian cells. Molecular and Cellular Biology 7, 725-737.
    [Google Scholar]
  9. Dong, X.-P., Stubenrauch, F., Beyer-Finkler, E. & Pfister, H. ( 1994; ). Prevalence of deletions of YY1-binding sites in episomal HPV 16 DNA from cervical cancers. International Journal of Cancer 58, 803-808.[CrossRef]
    [Google Scholar]
  10. Dostatni, N., Lambert, P. F., Sousa, R., Ham, J., Howley, P. M. & Yaniv, M. ( 1991; ). The functional BPV-1 E2 trans-activating protein can act as a repressor by preventing formation of the initiation complex. Genes & Development 5, 1657-1671.[CrossRef]
    [Google Scholar]
  11. Dyson, N., Howley, P. M., Münger, K. & Harlow, E. ( 1989; ). The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science 243, 934-937.[CrossRef]
    [Google Scholar]
  12. Hoppe-Seyler, F., Butz, K. & zur Hausen, H. ( 1991; ). Repression of the human papillomavirus type 18 enhancer by the cellular transcription factor Oct-1. Journal of Virology 65, 5613-5618.
    [Google Scholar]
  13. Ishiji, T., Lace, M. J., Parkkinen, S., Anderson, R. D., Haugen, T. H., Cripe, T. P., Xiao, J.-H., Davidson, I., Chambon, P. & Turek, L. P. ( 1992; ). Transcriptional enhancer factor (TEF)-1 and its cell-specific co-activator activate human papillomavirus-16 E6 and E7 oncogene transcription in keratinocytes and cervical carcinoma cells. EMBO Journal 11, 2271-2281.
    [Google Scholar]
  14. Kyo, S., Inoue, M., Nishio, Y., Nakanishi, K., Akira, S., Inoue, H., Yutsudo, M., Tanizawa, O. & Hakura, A. ( 1993; ). NF-IL6 represses early gene expression of human papillomavirus type 16 through binding to the noncoding region. Journal of Virology 67, 1058-1066.
    [Google Scholar]
  15. Kyo, S., Tam, A. & Laimins, L. A. ( 1995; ). Transcriptional activity of human papillomavirus type 31b enhancer is regulated through synergistic interaction of AP1 with two novel cellular factors. Virology 211, 184-197.[CrossRef]
    [Google Scholar]
  16. Londesborough, P., Ho, L., Terry, G., Cuzick, J., Wheeler, C. M. & Singer, A. ( 1996; ). Human papillomavirus genotype as a predictor of persistence and development of high-grade lesions in women with minor cervical abnormalities. International Journal of Cancer 69, 364-368.[CrossRef]
    [Google Scholar]
  17. Mittal, R., Pater, A. & Pater, M. M. ( 1993; ). Multiple human papillomavirus type 16 glucocorticoid response elements functional for transformation, transient expression, and DNA–protein interactions. Journal of Virology 67, 5656-5659.
    [Google Scholar]
  18. Münger, K., Phelps, W. C., Bubb, V., Howley, P. M. & Schlegel, R. ( 1989; ). The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. Journal of Virology 63, 4417-4421.
    [Google Scholar]
  19. O’Connor, M. & Bernard, H.-U. ( 1995; ). Oct-1 activates the epithelial-specific enhancer of human papillomavirus type 16 via a synergistic interaction with NF1 at a conserved composite regulatory element. Virology 207, 77-88.[CrossRef]
    [Google Scholar]
  20. O’Connor, M. J., Tan, S.-H., Tan, C.-H. & Bernard, H.-U. ( 1996; ). YY1 represses human papillomavirus type 16 transcription by quenching AP-1 activity. Journal of Virology 70, 6529-6539.
    [Google Scholar]
  21. Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J. & Howley, P. M. ( 1990; ). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53. Cell 63, 1129-1136.[CrossRef]
    [Google Scholar]
  22. Steger, G. & Corbach, S. ( 1997; ). Dose-dependent regulation of the early promoter of human papillomavirus type 18 by the viral E2 protein. Journal of Virology 71, 50-58.
    [Google Scholar]
  23. Stöppler, M. C., Ching, K., Stöppler, H., Clancy, K., Schlegel, R. & Icenogle, J. ( 1996; ). Natural variants of the human papillomavirus type 16 E6 protein differ in their abilities to alter keratinocyte differentiation and to induce p53 degradation. Journal of Virology 70, 6987-6993.
    [Google Scholar]
  24. Tan, S.-H., Leong, L. E.-C., Walker, P. A. & Bernard, H.-U. ( 1994; ). The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID. Journal of Virology 68, 6411-6420.
    [Google Scholar]
  25. Veress, G., Szarka, K., Dong, X.-P., Gergely, L. & Pfister, H. ( 1999; ). Functional significance of sequence variation in the E2 gene and the long control region of human papillomavirus type 16. Journal of General Virology 80, 1035-1043.
    [Google Scholar]
  26. Wheeler, C. M., Yamada, T., Hildesheim, A. & Jenison, S. A. ( 1997; ). Human papillomavirus type 16 sequence variants: identification by E6 and L1 lineage-specific hybridization. Journal of Clinical Microbiology 35, 11-19.
    [Google Scholar]
  27. Xi, L. F., Koutsky, L. A., Galloway, D. A., Kuypers, J., Hughes, J. P., Wheeler, C. M., Holmes, K. K. & Kiviat, N. B. ( 1997; ). Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. Journal of the National Cancer Institute 89, 796-802.[CrossRef]
    [Google Scholar]
  28. Xi, L. F., Critchlow, C. W., Wheeler, C. M., Koutsky, L. A., Galloway, D. A., Kuypers, J., Hughes, J. P., Hawes, S. E., Surawicz, C., Goldbaum, G., Holmes, K. K. & Kiviat, N. B. ( 1998; ). Risk of anal carcinoma in situ in relation to human papillomavirus type 16 variants. Cancer Research 58, 3839-3844.
    [Google Scholar]
  29. Yamada, T., Wheeler, C. M., Halpern, A. L., Stewart, A. C., Hildesheim, A. & Jenison, S. A. ( 1995; ). Human papillomavirus type 16 variant lineages in United States populations characterized by nucleotide sequence analysis of the E6, L2, and L1 coding segments. Journal of Virology 69, 7743-7753.
    [Google Scholar]
  30. Yamada, T., Manos, M. M., Peto, J., Greer, C. E., Muñoz, N., Bosch, F. X. & Wheeler, C. M. ( 1997; ). Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. Journal of Virology 71, 2463-2472.
    [Google Scholar]
  31. Zehbe, I., Wilander, E., Delius, H. & Tommasino, M. ( 1998; ). Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Research 58, 829-833.
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-81-8-1975
Loading
/content/journal/jgv/10.1099/0022-1317-81-8-1975
Loading

Data & Media loading...

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error